graph Evidence gap map comparisons
nivolumab based treatmentpembrolizumab based treatment
nivolumab plus SoC pembrolizumab alone pembrolizumab plus SoC
mGC or mGEJC - 1st line (L1)
mGC or mGEJC - L1 - all population
mGC or mGEJC - L1 - HER2 neg/PDL1 positive 2    
mGC or mGEJC - L1 - HER2 negative 1   
mGC or mGEJC - L1 - HER2 positive
mGC or mGEJC - L1 - PDL1 positive 4       
Comparator:  vs Standard of Care (SoC);   vs placebo plus SoC; 
Risk of bias:  low;   some concerns;   high;  NA;